Literature DB >> 12204627

The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics.

P L Toutain1, J R E del Castillo, A Bousquet-Mélou.   

Abstract

Pharmacokinetic-pharmacodynamic (PK/PD) surrogate indices (AUIC, AUC/MIC, C(max)/MIC, T>MIC) for measuring antibiotic efficacy are presented and reviewed. As clinical trials are not sufficiently sensitive to establish a dosage regimen which guarantees total bacteriological cure (Pollyanna phenomenon), PK/PD indexes have been proposed from in vitro, ex vivo, and in vivo infection models and subsequently validated in retrospective or prospective human clinical trials. The target value for time-dependent antibiotics (beta-lactams, macrolides) is a time above the MIC (T>MIC) of 50-80% of the dosage interval, while for concentration-dependent antibiotics (quinolones and aminoglycosides), the area under the inhibitory curve (AUIC, or more simply AUC/MIC of about 125h) is the best surrogate indicator of activity. Using the latter drugs, high concentrations achieved early during therapy are desirable to prevent the development of resistance. A C(max)/MIC ratio greater than 10-12 seems to be an appropriate target for aminoglycosides.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204627     DOI: 10.1016/s0034-5288(02)00039-5

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  76 in total

1.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

2.  Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.

Authors:  Aneliya Milanova Haritova; Nikolina Velizarova Rusenova; Parvan Rusenov Parvanov; Lubomir Dimitrov Lashev; Johanna Fink-Gremmels
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Pharmacokinetics and bioavailability of florfenicol following intravenous, intramuscular and oral administrations in rabbits.

Authors:  A M Abd El-Aty; A Goudah; K Abo El-Sooud; H Y El-Zorba; M Shimoda; H H Zhou
Journal:  Vet Res Commun       Date:  2004-08       Impact factor: 2.459

Review 4.  Antibiotic resistome of Salmonella typhi: molecular determinants for the emergence of drug resistance.

Authors:  Awanish Kumar; Anil Kumar
Journal:  Front Med       Date:  2021-06-04       Impact factor: 4.592

Review 5.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Pharmacokinetics, urinary excretion and plasma protein binding of danofloxacin following intravenous administration in buffalo calves (Bubalus bubalis).

Authors:  Ravinder Sappal; Rakesh Kumar Chaudhary; Harpal Singh Sandhu; Pritam Kaur Sidhu
Journal:  Vet Res Commun       Date:  2009-03-19       Impact factor: 2.459

Review 7.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Comparative pharmacokinetics of cefuroxime lysine after single intravenous, intraperitoneal, and intramuscular administration to rats.

Authors:  Long-shan Zhao; Ran Yin; Bin-bin Wei; Qing Li; Zhen-yuan Jiang; Xiao-hui Chen; Kai-shun Bi
Journal:  Acta Pharmacol Sin       Date:  2012-10-15       Impact factor: 6.150

9.  Disposition kinetics of levofloxacin in sheep after intravenous and intramuscular administration.

Authors:  Ayman Goudah; Sherifa Hasabelnaby
Journal:  Vet Med Int       Date:  2010-11-02

10.  Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs.

Authors:  Zhi-Qiang Chang; Byung-Chol Oh; Jong-Choon Kim; Kyu-Shik Jeong; Myung-Heon Lee; Hyo-In Yun; Mi-Hyun Hwang; Seung-Chun Park
Journal:  J Vet Sci       Date:  2007-12       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.